Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 2.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.98M |
| Shares Out | 1.43M |
| EPS (ttm) | -11.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,009 |
| Open | 1.570 |
| Previous Close | 1.560 |
| Day's Range | 1.530 - 1.580 |
| 52-Week Range | 1.510 - 30.250 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 37.50 (+2,311.58%) |
| Earnings Date | May 14, 2026 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ADIL stock is "Strong Buy" and the 12-month stock price target is $37.5.
News
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatme...
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product produc...
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Subm...
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 development Partnership has ...
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder FDA Minutes Reflect Constructive Dial...
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies fo...
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ad...
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement
GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstr...
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Milestone Achieved as Adovate Initiates First-in-Human Study fo...
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spe...
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies fo...
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence New Patent expands patent estate covering Adial's...
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...